- Home
- SB vs SRRK Comparison
SB vs SRRK Comparison
Compare SB & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- SRRK
- Stock Information
- Founded
- SB 2007
- SRRK 2012
- Country
- SB Monaco
- SRRK United States
- Employees
- SB N/A
- SRRK N/A
- Industry
- SB Marine Transportation
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SB Consumer Discretionary
- SRRK Health Care
- Exchange
- SB Nasdaq
- SRRK Nasdaq
- Market Cap
- SB 454.8M
- SRRK 2.8B
- IPO Year
- SB 2008
- SRRK 2018
- Fundamental
- Price
- SB $4.34
- SRRK $29.08
- Analyst Decision
- SB
- SRRK Strong Buy
- Analyst Count
- SB 0
- SRRK 7
- Target Price
- SB N/A
- SRRK $33.29
- AVG Volume (30 Days)
- SB 570.1K
- SRRK 1.2M
- Earning Date
- SB 11-13-2024
- SRRK 11-12-2024
- Dividend Yield
- SB 4.61%
- SRRK N/A
- EPS Growth
- SB N/A
- SRRK N/A
- EPS
- SB 0.80
- SRRK N/A
- Revenue
- SB $307,156,000.00
- SRRK N/A
- Revenue This Year
- SB $9.46
- SRRK N/A
- Revenue Next Year
- SB N/A
- SRRK N/A
- P/E Ratio
- SB $5.46
- SRRK N/A
- Revenue Growth
- SB N/A
- SRRK N/A
- 52 Week Low
- SB $3.16
- SRRK $6.76
- 52 Week High
- SB $6.33
- SRRK $35.38
- Technical
- Relative Strength Index (RSI)
- SB 43.58
- SRRK 61.66
- Support Level
- SB $4.11
- SRRK $26.89
- Resistance Level
- SB $4.45
- SRRK $30.97
- Average True Range (ATR)
- SB 0.10
- SRRK 1.52
- MACD
- SB 0.03
- SRRK -0.78
- Stochastic Oscillator
- SB 67.65
- SRRK 50.37
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.